SheppardMullin

Scott S. Liebman

Partner
30 Rockefeller Plaza
New York, NY 10112

T: +1.212.634.3030
sliebman@sheppardmullin.com

Scott Liebman is Leader of the firm's Life Sciences Team and is based in the firm's New York office.

Areas of Practice

Scott focuses on complex FDA regulatory, compliance and legal matters affecting global pharmaceutical, biotechnology and medical device manufacturers. He counsels clients on federal and state requirements and develops legal and regulatory strategies to help commercialize their products.

Clients regularly turn to Scott and his team to support product launches; implement corporate integrity agreements; develop comprehensive training and monitor compliance programs; and handle anti-kickback, sampling and off-label investigations. Whether advising executives or training a national sales force, Scott knows that clear, thoughtful communication and practical advice are key to supporting his clients.

He has worked with businesses of all sizes, from small life sciences organizations launching their first product to Fortune 500 companies in the pharmaceutical and medical products/equipment industries. His clients operate worldwide and include Europe- and Asia-based life sciences companies.

Scott is passionate about understanding his clients' challenges and is committed to learning their businesses inside and out to find solutions. He brings deep technical knowledge along with enthusiasm for his clients' work to each client relationship.

Honors

Leading Life Sciences Lawyer - FDA Medical Device and FDA Pharmaceutical, *LMG Life Sciences*, 2021-2023

Health Care Trailblazer, The National Law Journal, 2020

Rising Star, the New York Law Journal, 2014

New Leaders of The Bar, New Jersey Law Journal, 2012

New York Metro Rising Star in Health Care Law, Thomson Reuters, 2014-2015

New Jersey Rising Star in Health Care Law, Thomson Reuters, 2013

Articles

- FDA Warning Letter Tightens Reins On 'Research Only' Labels
  Law360, 04.22.2024

- 2024 Top-of-Mind Issues for Life Sciences Companies
  01.25.2024
- Tech Support: FDA's Evolving Regulatory Plan for Drug- and Device-Enabling Software
  Food and Drug Law Institute, 12.15.2023
- 2023 Top-of-Mind Issues for Life Sciences Companies
  01.11.2023
- 6 Takeaways From LabSolutions 'Unnecessary Testing' Verdict
  Law360, 01.11.2023
- Industry Fights Back Against Restrictions on Pharmaceutical Manufacturers' Ability To Offer Drug Cost-Sharing Subsidies
  New York Law Journal, 01.09.2023
- OIG Advisory: Yet Another Favorable Decision for Medical Device Manufacturers
  New York Law Journal, 03.23.2022

FDA Law Blog Posts

- "FDA Warning Letter Regulates 'Research Only' Labels," April 24, 2024
- "2024 Top-of-Mind Issues for Life Sciences Companies," January 25, 2024
- "OIG General Compliance Program Guidance November 2023," November 8, 2023
- "OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers," March 17, 2022

Events

2024 FDLI Annual Conference
Washington, DC, May 15-16, 2024

Pharmaceutical Compliance Congress 2024
April 16-18, 2024

2023 FDLI Annual Conference
May 17-18, 2023

Practices

FDA Regulatory

Governmental Practice

Intellectual Property

Veterinary Health

Industries

Life Sciences

Education

J.D., Seton Hall University Law School

B.A., Lehigh University

Admissions

New York

New Jersey

District of Columbia